CN1215853C - Traditional Chinese medicine for curing arrhythmia and its preparation - Google Patents
Traditional Chinese medicine for curing arrhythmia and its preparation Download PDFInfo
- Publication number
- CN1215853C CN1215853C CN 01131734 CN01131734A CN1215853C CN 1215853 C CN1215853 C CN 1215853C CN 01131734 CN01131734 CN 01131734 CN 01131734 A CN01131734 A CN 01131734A CN 1215853 C CN1215853 C CN 1215853C
- Authority
- CN
- China
- Prior art keywords
- radix
- clear paste
- mixing
- powder
- rhizoma nardostachyos
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 238000002360 preparation method Methods 0.000 title claims abstract description 18
- 239000003814 drug Substances 0.000 title claims description 39
- 206010003119 arrhythmia Diseases 0.000 title abstract description 6
- 230000006793 arrhythmia Effects 0.000 title abstract description 6
- 235000003143 Panax notoginseng Nutrition 0.000 claims abstract description 35
- 241000180649 Panax notoginseng Species 0.000 claims abstract description 35
- 239000008187 granular material Substances 0.000 claims abstract description 8
- 239000002775 capsule Substances 0.000 claims abstract description 6
- 239000000843 powder Substances 0.000 claims description 57
- 238000002156 mixing Methods 0.000 claims description 36
- 239000007864 aqueous solution Substances 0.000 claims description 18
- 238000004821 distillation Methods 0.000 claims description 18
- 239000000341 volatile oil Substances 0.000 claims description 18
- 241000756943 Codonopsis Species 0.000 claims description 15
- 238000000034 method Methods 0.000 claims description 10
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 10
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 9
- 238000001035 drying Methods 0.000 claims description 9
- 239000000706 filtrate Substances 0.000 claims description 9
- 239000007788 liquid Substances 0.000 claims description 9
- 238000010992 reflux Methods 0.000 claims description 9
- 239000000243 solution Substances 0.000 claims description 9
- 229920002472 Starch Polymers 0.000 claims description 6
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 claims description 6
- 239000008107 starch Substances 0.000 claims description 6
- 235000019698 starch Nutrition 0.000 claims description 6
- 229920001353 Dextrin Polymers 0.000 claims description 3
- 239000004375 Dextrin Substances 0.000 claims description 3
- 229930006000 Sucrose Natural products 0.000 claims description 3
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 claims description 3
- 239000011248 coating agent Substances 0.000 claims description 3
- 238000000576 coating method Methods 0.000 claims description 3
- 235000019425 dextrin Nutrition 0.000 claims description 3
- 238000005469 granulation Methods 0.000 claims description 3
- 230000003179 granulation Effects 0.000 claims description 3
- 235000019359 magnesium stearate Nutrition 0.000 claims description 3
- 239000000463 material Substances 0.000 claims description 3
- 239000002245 particle Substances 0.000 claims description 3
- 239000007921 spray Substances 0.000 claims description 3
- 239000005720 sucrose Substances 0.000 claims description 3
- 239000000284 extract Substances 0.000 claims 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 22
- 201000010099 disease Diseases 0.000 abstract description 20
- 210000004369 blood Anatomy 0.000 abstract description 14
- 239000008280 blood Substances 0.000 abstract description 14
- 230000000694 effects Effects 0.000 abstract description 13
- 206010033557 Palpitations Diseases 0.000 abstract description 11
- 239000002994 raw material Substances 0.000 abstract description 10
- 230000017531 blood circulation Effects 0.000 abstract description 6
- 239000003826 tablet Substances 0.000 abstract description 4
- 230000001502 supplementing effect Effects 0.000 abstract description 3
- 230000004069 differentiation Effects 0.000 abstract description 2
- 230000006870 function Effects 0.000 abstract description 2
- 230000036541 health Effects 0.000 abstract description 2
- 241000722818 Aralia Species 0.000 abstract 1
- 235000014722 Aralia cordata Nutrition 0.000 abstract 1
- 235000004446 Aralia racemosa Nutrition 0.000 abstract 1
- 235000010658 Lavandula latifolia Nutrition 0.000 abstract 1
- 241000756042 Polygonatum Species 0.000 abstract 1
- 235000008737 Polygonatum biflorum Nutrition 0.000 abstract 1
- 230000003213 activating effect Effects 0.000 abstract 1
- 230000002763 arrhythmic effect Effects 0.000 abstract 1
- 230000010349 pulsation Effects 0.000 abstract 1
- 230000000087 stabilizing effect Effects 0.000 abstract 1
- 208000011580 syndromic disease Diseases 0.000 abstract 1
- 208000000059 Dyspnea Diseases 0.000 description 7
- 206010013975 Dyspnoeas Diseases 0.000 description 7
- 230000002354 daily effect Effects 0.000 description 7
- 208000013220 shortness of breath Diseases 0.000 description 7
- 208000002193 Pain Diseases 0.000 description 6
- 208000002173 dizziness Diseases 0.000 description 6
- LOUPRKONTZGTKE-LHHVKLHASA-N quinidine Chemical compound C([C@H]([C@H](C1)C=C)C2)C[N@@]1[C@H]2[C@@H](O)C1=CC=NC2=CC=C(OC)C=C21 LOUPRKONTZGTKE-LHHVKLHASA-N 0.000 description 6
- 206010040007 Sense of oppression Diseases 0.000 description 5
- 230000009429 distress Effects 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 230000001737 promoting effect Effects 0.000 description 4
- 239000011800 void material Substances 0.000 description 4
- LOUPRKONTZGTKE-UHFFFAOYSA-N cinchonine Natural products C1C(C(C2)C=C)CCN2C1C(O)C1=CC=NC2=CC=C(OC)C=C21 LOUPRKONTZGTKE-UHFFFAOYSA-N 0.000 description 3
- 235000009508 confectionery Nutrition 0.000 description 3
- 230000003203 everyday effect Effects 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- 230000008506 pathogenesis Effects 0.000 description 3
- 229960001404 quinidine Drugs 0.000 description 3
- 101710088194 Dehydrogenase Proteins 0.000 description 2
- 206010062717 Increased upper airway secretion Diseases 0.000 description 2
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 2
- 210000001367 artery Anatomy 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 208000029078 coronary artery disease Diseases 0.000 description 2
- 230000007812 deficiency Effects 0.000 description 2
- 208000001780 epistaxis Diseases 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 230000004217 heart function Effects 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 206010022437 insomnia Diseases 0.000 description 2
- 230000010354 integration Effects 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 230000014759 maintenance of location Effects 0.000 description 2
- 230000002107 myocardial effect Effects 0.000 description 2
- 208000026435 phlegm Diseases 0.000 description 2
- 230000007958 sleep Effects 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 210000003462 vein Anatomy 0.000 description 2
- PTTPXKJBFFKCEK-UHFFFAOYSA-N 2-Methyl-4-heptanone Chemical compound CC(C)CC(=O)CC(C)C PTTPXKJBFFKCEK-UHFFFAOYSA-N 0.000 description 1
- 241000227129 Aconitum Species 0.000 description 1
- 206010002383 Angina Pectoris Diseases 0.000 description 1
- 206010003658 Atrial Fibrillation Diseases 0.000 description 1
- 206010003662 Atrial flutter Diseases 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 206010008479 Chest Pain Diseases 0.000 description 1
- 239000003390 Chinese drug Substances 0.000 description 1
- 206010010904 Convulsion Diseases 0.000 description 1
- 241000208011 Digitalis Species 0.000 description 1
- 208000015220 Febrile disease Diseases 0.000 description 1
- 208000012671 Gastrointestinal haemorrhages Diseases 0.000 description 1
- 229920002527 Glycogen Polymers 0.000 description 1
- NNJVILVZKWQKPM-UHFFFAOYSA-N Lidocaine Chemical compound CCN(CC)CC(=O)NC1=C(C)C=CC=C1C NNJVILVZKWQKPM-UHFFFAOYSA-N 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 208000004880 Polyuria Diseases 0.000 description 1
- 208000032023 Signs and Symptoms Diseases 0.000 description 1
- 206010042434 Sudden death Diseases 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- 230000000202 analgesic effect Effects 0.000 description 1
- 230000003288 anthiarrhythmic effect Effects 0.000 description 1
- 230000004856 capillary permeability Effects 0.000 description 1
- 239000000496 cardiotonic agent Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 230000036461 convulsion Effects 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 238000003748 differential diagnosis Methods 0.000 description 1
- 230000035619 diuresis Effects 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 230000037149 energy metabolism Effects 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 206010016256 fatigue Diseases 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 229940096919 glycogen Drugs 0.000 description 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
- 239000010931 gold Substances 0.000 description 1
- 229910052737 gold Inorganic materials 0.000 description 1
- 208000019622 heart disease Diseases 0.000 description 1
- 208000035861 hematochezia Diseases 0.000 description 1
- 208000015210 hypertensive heart disease Diseases 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000003907 kidney function Effects 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 229960004194 lidocaine Drugs 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 230000002175 menstrual effect Effects 0.000 description 1
- 208000010125 myocardial infarction Diseases 0.000 description 1
- 210000004165 myocardium Anatomy 0.000 description 1
- 231100000957 no side effect Toxicity 0.000 description 1
- 229940126701 oral medication Drugs 0.000 description 1
- 239000007935 oral tablet Substances 0.000 description 1
- 229940096978 oral tablet Drugs 0.000 description 1
- 230000036284 oxygen consumption Effects 0.000 description 1
- 229960002790 phenytoin sodium Drugs 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- JWHAUXFOSRPERK-UHFFFAOYSA-N propafenone Chemical compound CCCNCC(O)COC1=CC=CC=C1C(=O)CCC1=CC=CC=C1 JWHAUXFOSRPERK-UHFFFAOYSA-N 0.000 description 1
- 229960000203 propafenone Drugs 0.000 description 1
- 230000005180 public health Effects 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000033764 rhythmic process Effects 0.000 description 1
- 208000037921 secondary disease Diseases 0.000 description 1
- FJPYVLNWWICYDW-UHFFFAOYSA-M sodium;5,5-diphenylimidazolidin-1-ide-2,4-dione Chemical compound [Na+].O=C1[N-]C(=O)NC1(C=1C=CC=CC=1)C1=CC=CC=C1 FJPYVLNWWICYDW-UHFFFAOYSA-M 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 238000005728 strengthening Methods 0.000 description 1
- 235000019640 taste Nutrition 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 230000002936 tranquilizing effect Effects 0.000 description 1
- 238000002562 urinalysis Methods 0.000 description 1
- 230000008673 vomiting Effects 0.000 description 1
- 239000008945 zhigancao decoction Substances 0.000 description 1
Landscapes
- Medicines Containing Plant Substances (AREA)
- Medicinal Preparation (AREA)
Abstract
The present invention relates to a pure Chinese herb preparation for treating arrhythmia, which is prepared from raw materials of pilose asiabell root, solomonseal rhizome, notoginseng, amber, spikenard, etc. as basic prescriptions and is scientifically processed according to a principle of syndrome differentiation and treatment relevant to radical reform and both treatment of manifestation and roots in the traditional medical science. The preparation form comprises granules, capsules and tablets. The preparation has the functions of supplementing qi, nourishing yin, stabilizing palpitation, relieving pulsation activating blood circulation and removing blood stasis, has excellent effect on arrhythmic treatment aspects and is capable of obviously reducing or eliminating the threat of the class of diseases to people health.
Description
Content of the present invention belongs to the preparing technical field of pharmaceuticals, relates to a kind of ARR pure Chinese medicinal preparation and preparation method thereof that can be used for treating.
Arrhythmia in the modern medicine surely belongs to " cardiopalmus ", " palpitation with a distress feeling " category in the Chinese medicine, be one of the commonly encountered diseases of cardiovascular disease and frequently-occurring disease, its clinical manifestation is a kind of rule of unexpected generation or erratic cardiopalmus, chest pain, dizzy, pareordia sense of discomfort, feel oppressed, shortness of breath and fatigue, hands and feet coolness and faint, be common in the heart patient (as coronary heart disease, myocardial infarction, hypertensive heart disease patient etc.) of a variety of causes, also be found in no organic heart disease people.Since arrhythmia disease have morbidity anxious, change fast, can repeatedly fall ill and disable, characteristics such as sudden death rate height, the healthy of the healthy particularly mid-aged population of people in serious harm, thereby it is that medical circle is concentrated the heat subject of paying close attention to and endeavouring to research and solve always for a long time.
At present, the present technique field is used for the treatment of ARR drug main will propafenone, Folium Digitalis Purpureae, phenytoin Sodium, lignocaine, quinidine etc., though all have certain curative effect, but in the clinical practice yet corresponding exist medication not comprehensively, problem such as curative effect is unstable and cure rate is low, some medicine also can produce some untoward reaction even toxic side effect to human body.
The objective of the invention is at the existing above-mentioned defective of state of the art, by excavating the abundant Chinese medicine resource of motherland, and then provide the novel science of a kind of prescription, easy to prepare, curative effect is high and be exclusively used in the ARR pure Chinese medicinal preparation of treatment to what human body had no side effect, and provide simultaneously and be exclusively used in the preparation method of producing this Chinese medicine preparation.
The preparation scheme of medicine of the present invention comes from motherland's medical science about traditional determination of treatment based on pathogenesis obtained through differentiation of symptoms and signs thought such as " radicallying reform ", " treating both the principal and secondary aspects of a disease " and on the extensive experiment basis and obtain.The etiology and pathogenesis of cardiopalmus, palpitation with a distress feeling, ancient Chinese medicine doctor is many at all times is this with the deficiency of vital energy, blood stasis is mark.Zhang Zhongjing head goes out the view of " interior deficiency " as the Han dynasty, establish in its treatise on Febrile Diseases Xiao Jianzhong Tang control throb with fear, disease such as nosebleed, the disease of upright zhigancao decoction doctor irregularly intermittent and regularly intermittent pulse, severe palpitation; " Medical Treasures of the Golden Chamber, vomiting caused by fright in infant nosebleed hematochezia fullness in the chest blood stasis disease " clearly proposes again: " pulse at CUN KOU being tremulous and weak, moving then for throbbing with fear "; Gold dollar Zhu Dan small stream is also said: " palpitation with a distress feeling person, know void, when palpitation with a distress feeling did not have, the insufficiency of blood person was many "; Clear Golden Mirror of Medicine think " throb with fear also from interior cautious person, throb with fear because of in void, so weak pulse and unable "; Except that main " void ", still there are main phlegm-fire, main diseases caused by retention of fluid, the main stagnation of QI, main blood stasis person in doctor family, but from the etiology and pathogenesis analysis, when being in secondary disease because of the position, all can not mention in the same breath with " void ", be this so the treatment of this disease is worked as with weakened body resistance, and the phlegm retention fire of moxibustion stasis of blood is mark, then suitable giving consideration to both the incidental and fundamental makes it reach on the method for treatment.Chinese medicine preparation of the present invention promptly is on this basis and in conjunction with designer's clinical practice for many years, dialectically combine with differential diagnosis of diseases, by to motherland's Chinese medicine resource selected making in addition, medicine material in the side is made up of Radix Codonopsis, Rhizoma Polygonati, Radix Notoginseng, succinum, the Radix Et Rhizoma Nardostachyos meter five tastes, full side has supplementing QI and nourishing YIN, the throb with fear effect of multiple arteries and veins, blood circulation promoting and blood stasis dispelling surely, aspect ARR treatment, fabulous effect is being arranged, can significantly reduce or eliminate of the threat of this type of disease health of people.
The weight proportion of forming each medicine material of Chinese drugs agentia of the present invention is: 50～500 unit of weights of Radix Codonopsis, 30～700 unit of weights of Rhizoma Polygonati, 20～200 unit of weights of Radix Notoginseng, 5～80 unit of weights of succinum, 50～400 unit of weights of Radix Et Rhizoma Nardostachyos.
In the said medicine prescription, Radix Codonopsis sweet in the mouth, warm in nature, return spleen, stomach two warps, have invigorate vital energy and reinforce the heart, the effect of blood circulation promoting and blood stasis dispelling, animal experiment proof Radix Codonopsis can obviously improve the content of mouse cardiac muscle glycogen, succinum dehydrogenase and lactic acid dehydrogenase, illustrates that it is the cardiac stimulant mechanism of action of QI invigorating that Radix Codonopsis improves energy metabolism of myocardial; Rhizoma Polygonati is grown greasy, and for nourishing the thing of cloudy blood, it also has the heart tonifying effect concurrently simultaneously; The function of Radix Notoginseng is clots absorbing, analgesic therapy, can be used for strengthening cardiac function clinically, reduces aspects such as myocardial oxygen consumption, coronary blood flow increasing, reduction capillary permeability; Succinum is flat, sweet in the mouth, except that being used for tranquillizing the mind by relieving convulsion, promoting blood circulation to restore menstrual flow, the broken disease of dissipating blood stasis, also has the effect of inducing diuresis to remove edema; Warm in nature, the sweet in the mouth of Radix Et Rhizoma Nardostachyos, but imitate regulating QI to relieve pain, the modern pharmacy test shows that the valerone in the Radix Et Rhizoma Nardostachyos has antiarrhythmic effect, and its inhibition to the dystopy sinus rhythm is better than quinidine, and is then identical with quinidine in the inhibition aspect damaging atrial flutter and Aconitum carmichjaelii Debx. alkalescence atrial fibrillation.More than five medicines be combined into a side, power is specially imitated grand, plays supplementing QI and nourishing YIN, the throb with fear merit of multiple arteries and veins, blood circulation promoting and blood stasis dispelling surely altogether, can make gradually foot of patient's motive, the heart-yin must be filled, the stasis of blood dispel ruton, QI and blood smoothness, then all diseases of shortness of breath and palpitation are from removing.
In the concrete preparation of actual product of the present invention, this medicine that is used for the treatment of arrhythmia disease can be processed into granule, capsule, three kinds of preparation formulations of tablet by the base stock composition, the preparation method of each dosage form is as described below.
One, the method for making of granule:
Succinum powder in the raw material is broken into fine powder, in addition the Radix Et Rhizoma Nardostachyos in the raw material is extracted volatile oil, the aqueous solution after distillation device is in addition collected; Radix Notoginseng powder in the raw material is become coarse powder, add 50%～80% alcohol reflux 2～3 times, each 1～3 hour, filter, merging solution and its concentrating under reduced pressure is become relative density is the Radix Notoginseng clear paste of 1.25～1.30 (60 ℃ of surveys); Get Radix Notoginseng, Radix Et Rhizoma Nardostachyos medicinal residues Radix Codonopsis, the Rhizoma Polygonati in raw material and decoct with water secondary, 1～2 hour for the first time, 0.5～1.5 hour for the second time, aqueous solution after the distillation of twice decocting liquid and aforementioned Radix Et Rhizoma Nardostachyos is merged, filter, filtrate is condensed into the clear paste that relative density is 1.20～1.25 (60 ℃ of surveys); With this clear paste and Radix Notoginseng clear paste merge, mixing, in mixing clear paste, add the succinum fine powder afterwards, add the dextrin of 100～550 unit of weights and the sucrose of 100～700 unit of weights again, mixing is made granule; To make particle drying, spray Radix et Rhizoma Nardostachyos volatile oil, mixing, pack, every bag of 9g.
Two, the method for making of capsule:
Succinum powder in the raw material is broken into fine powder and Radix Et Rhizoma Nardostachyos is extracted volatile oil, and the aqueous solution after distillation device is in addition collected; Radix Notoginseng powder in the raw material is broken into coarse powder, adds 50%～80% alcohol reflux 2～3 times, each 1～3 hour, filter, merging solution and its concentrating under reduced pressure is become relative density is the Radix Notoginseng clear paste of 1.25～1.30 (60 ℃ of surveys); Get Radix Notoginseng, Radix Et Rhizoma Nardostachyos medicinal residues Radix Codonopsis, the Rhizoma Polygonati in raw material and decoct with water secondary, 1～2 hour for the first time, 0.5～1.5 hour for the second time, aqueous solution after the distillation of twice decocting liquid and aforementioned Radix Et Rhizoma Nardostachyos is merged, filter, filtrate is condensed into the clear paste that relative density is 1.20～1.25 (60 ℃ of surveys); With this clear paste and Radix Notoginseng clear paste merge, mixing, in mixing clear paste, add the succinum fine powder afterwards, add the starch of 100～400 unit of weights again, mixing, drying, powder becomes fine powder, adds Radix et Rhizoma Nardostachyos volatile oil, mixing incapsulates, the heavily about 0.3～0.5g of every capsule.
Three, the method for making of tablet:
Succinum powder in the raw material is broken into fine powder, in addition Radix Et Rhizoma Nardostachyos is extracted volatile oil, the aqueous solution after distillation device is in addition collected; Radix Notoginseng powder is broken into coarse powder, adds 50%～80% alcohol reflux 2～3 times, each 1～3 hour, filter, merging solution and its concentrating under reduced pressure is become relative density is the Radix Notoginseng clear paste of 1.25～1.30 (60 ℃ of surveys); Get Radix Notoginseng, Radix Et Rhizoma Nardostachyos medicinal residues Radix Codonopsis, the Rhizoma Polygonati in raw material and decoct with water secondary, 1～2 hour for the first time, 0.5～1.5 hour for the second time, aqueous solution after the distillation of twice decocting liquid and aforementioned Radix Et Rhizoma Nardostachyos is merged, filter, filtrate is condensed into the clear paste that relative density is 1.20～1.25 (60 ℃ of surveys); With this clear paste and Radix Notoginseng clear paste merge, mixing, in mixing clear paste, add the succinum fine powder afterwards, mixing, drying, powder becomes fine powder; Add the starch of Radix et Rhizoma Nardostachyos volatile oil and 100～400 unit of weights and the magnesium stearate of 0.8～5 unit of weight again, mixing, granulation, tabletting, coating, every tablet of medicament weighs 0.3～0.5g.
Clinical observation and curative effect
312 examples of clinical observation case once in development process of the present invention, male's 181 examples wherein, women's 131 examples, patient age between 19～83 years old, 51.85 years old mean age, person's 231 examples more than 50 years old.
One, clinical disease: comprise palpitation and uneasiness primary symptom time and shortness of breath and fatigue, dizzy vexed, uneasy sleeping at night, 4 double diseases of feeling of oppression and pain in the chest.
Two, medicining mode: oral medicine granule, every day 3 times, each a bag (9g), warm boiled water; Or oral Drug Capsule agent, every day 3 times, each 4 (2g); Or oral tablet, every day 3 times, each 4 (2g).Be a course of treatment all around, finish the course of treatment, can sum up.
Three, efficacy determination index: adopt the primary symptom time of Ministry of Public Health " the national combination of Chinese and Western medicine in 1979 prevents coronary heart disease, angina pectoris, arrhythmia forum " formulation and the classification and the standards of grading of the disease of holding concurrently
1, palpitation and uneasiness
Do not have (-): disappeared 0 fen
Gently (+): can be competent at general daily work, but heavy physical labour is not peaceful 4 minutes of had palpitation slightly
In (++): general daily work is not peaceful 5 minutes of had palpitation
Heavy (+++): can not be engaged in any physical work, even also can occur cardiopalmus 6 minutes during rest
2, shortness of breath and fatigue
Do not have (-): disappeared 0 fen
Gently (+): trot in the level land, and shortness of breath and fatigue 1 minute is felt in the 3rd buildings on the quick or prudent thing slightly
In (++): shortness of breath and fatigue 2 minutes is promptly felt in daily physical exertion
Heavy (+++): also feel shortness of breath and fatigue 3 minutes when light physical exertion even rest
3, dizzy vexed
Do not have (-): disappeared 0 fen
Gently (+): trot in the level land, and felt dizzy vexed 1 minute slightly in the 3rd buildings on the quick or prudent thing
In (++): daily physical exertion was promptly felt dizzy vexed 2 minutes
Heavy (+++): also felt dizzy vexed 3 minutes when light physical exertion even rest
4, uneasy sleeping at night
Do not have (-): disappeared 0 fen
Gently (+): difficulty falling asleep sleeps less once in a while or be insomnia, or uneasy sleeping at night goes out continuously
The person is 1 minute in present three days
In (++): difficulty falling asleep, sleeping less or being insomnia often occurs, or uneasy sleeping at night
Appeared at person on the four to seven continuously 2 minutes
Heavy (+++): have difficulty in going to sleep even lie awake all night, or uneasy sleeping at night goes out continuously
Present person 3 minutes more than seven days
5, feeling of oppression and pain in the chest
Do not have (-): disappeared 0 fen
Gently (+): can be competent at general daily work, but heavy physical labour promptly had feeling of oppression and pain in the chest 1 minute slightly
In (++): daily physical work promptly had feeling of oppression and pain in the chest 2 minutes
Heavy (+++): also feel feeling of oppression and pain in the chest 3 minutes when lighter daily physical work even rest
Four, efficacy assessment standard
Produce effects: disease disappears or disease is improved ++, integration descends greater than 2 fens persons.
Effectively: the disease improvement+, 1 minute to 4 minutes person of integration decline.
Invalid: disease does not have the improvement or the person of increasing the weight of, promptly+and number no change or enhancer.
Five, therapeutic outcome
Above observation group 312 routine cases after taking Chinese medicine preparation of the present invention treatment, produce effects 208 examples, effective 88 examples, invalid 16 examples, total effective rate is 94.87%, obvious effective rate is 66.67%.Make discovery from observation in the treatment, this medicine all has in various degree cardiac function, hemorheology and improves (P＜0.05), takes the back blood, routine urinalysis and liver, renal function etc. are not all had any infringement yet.
Claims (10)
1, a kind ofly is used for the treatment of ARR Chinese medicine, it is characterized in that it is the medicament of being processed into by following materials of weight proportions: 50～500 unit of weights of Radix Codonopsis, 30～700 unit of weights of Rhizoma Polygonati, 20～200 unit of weights of Radix Notoginseng, 5～80 unit of weights of succinum, 50～400 unit of weights of Radix Et Rhizoma Nardostachyos.
2, the ARR Chinese medicine of treatment as claimed in claim 1 is characterized in that: the medicament of being processed into is a granule.
3, the ARR Chinese medicine of treatment as claimed in claim 2 is characterized in that it is made by following method: Succinum powder is broken into fine powder; Radix Et Rhizoma Nardostachyos extracts volatile oil, and the aqueous solution after distillation device is in addition collected; Radix Notoginseng powder is broken into coarse powder, adds 50%～80% alcohol reflux 2～3 times, and each 1～3 hour, filter, relative density is 1.25～1.30 clear paste when merging solution and its concentrating under reduced pressure being become 60 ℃; Get Radix Notoginseng, the Radix Et Rhizoma Nardostachyos medicinal residues decoct with water secondary with Radix Codonopsis, Rhizoma Polygonati, 1～2 hour for the first time, 0.5～1.5 hour for the second time, make the aqueous solution merging after twice decocting liquid and the distillation of aforementioned Radix Et Rhizoma Nardostachyos, filter, relative density was 1.20～1.25 clear paste when filtrate was condensed into 60 ℃; With this clear paste and Radix Notoginseng clear paste merge, mixing, in mixing clear paste, add the succinum fine powder afterwards, add the dextrin of 100～550 unit of weights and the sucrose of 100～700 unit of weights again, mixing is made granule; With the particle drying that makes, the spray Radix et Rhizoma Nardostachyos volatile oil, mixing, promptly.
4, the ARR Chinese medicine of treatment as claimed in claim 1 is characterized in that: the medicament of being processed into is a capsule.
5, the ARR Chinese medicine of treatment as claimed in claim 4, it is characterized in that it is made by following method: Succinum powder is broken into fine powder; Radix Et Rhizoma Nardostachyos extracts volatile oil, and the aqueous solution after distillation device is in addition collected; Radix Notoginseng powder is broken into coarse powder, adds 50%～80% alcohol reflux 2～3 times, and each 1～3 hour, filter, relative density is 1.25～1.30 clear paste when merging solution and its concentrating under reduced pressure being become 60 ℃; Get Radix Notoginseng, the Radix Et Rhizoma Nardostachyos medicinal residues decoct with water secondary with Radix Codonopsis, Rhizoma Polygonati, 1～2 hour for the first time, 0.5～1.5 hour for the second time, make the aqueous solution merging after twice decocting liquid and the distillation of aforementioned Radix Et Rhizoma Nardostachyos, filter, relative density was 1.20～1.25 clear paste when filtrate was condensed into 60 ℃; With this clear paste and Radix Notoginseng clear paste merge, mixing, in mixing clear paste, add the succinum fine powder afterwards, add the starch of 100～400 unit of weights again, mixing, drying, powder becomes fine powder, adds Radix et Rhizoma Nardostachyos volatile oil, mixing incapsulates, promptly.
6, the ARR Chinese medicine of treatment as claimed in claim 1 is characterized in that: the medicament of being processed into is a tablet.
7, the ARR Chinese medicine of treatment as claimed in claim 6, it is characterized in that it is made by following method: Succinum powder is broken into fine powder; Radix Et Rhizoma Nardostachyos extracts volatile oil, and the aqueous solution after distillation device is in addition collected; Radix Notoginseng powder is broken into coarse powder, adds 50%～80% alcohol reflux 2～3 times, and each 1～3 hour, filter, relative density is 1.25～1.30 clear paste when merging solution and its concentrating under reduced pressure being become 60 ℃; Get Radix Notoginseng, the Radix Et Rhizoma Nardostachyos medicinal residues decoct with water secondary with Radix Codonopsis, Rhizoma Polygonati, 1～2 hour for the first time, 0.5～1.5 hour for the second time, make the aqueous solution merging after twice decocting liquid and the distillation of aforementioned Radix Et Rhizoma Nardostachyos, filter, relative density was 1.20～1.25 clear paste when filtrate was condensed into 60 ℃; With this clear paste and Radix Notoginseng clear paste merge, mixing, in mixing clear paste, add the succinum fine powder afterwards, mixing, drying, powder becomes fine powder; Add the starch of Radix et Rhizoma Nardostachyos volatile oil and 100～400 unit of weights and the magnesium stearate of 0.8～5 unit of weight again, mixing, granulation, tabletting, coating, promptly.
8, the ARR preparation method of Chinese medicine of a kind of treatment as claimed in claim 3, it is characterized in that: Succinum powder is broken into fine powder; Radix Et Rhizoma Nardostachyos extracts volatile oil, and the aqueous solution after distillation device is in addition collected; Radix Notoginseng powder is broken into coarse powder, adds 50%～80% alcohol reflux 2～3 times, and each 1～3 hour, filter, relative density is 1.25～1.30 clear paste when merging solution and its concentrating under reduced pressure being become 60 ℃; Get Radix Notoginseng, the Radix Et Rhizoma Nardostachyos medicinal residues decoct with water secondary with Radix Codonopsis, Rhizoma Polygonati, 1～2 hour for the first time, 0.5～1.5 hour for the second time, make the aqueous solution merging after twice decocting liquid and the distillation of aforementioned Radix Et Rhizoma Nardostachyos, filter, relative density was 1.20～1.25 clear paste when filtrate was condensed into 60 ℃; With this clear paste and Radix Notoginseng clear paste merge, mixing, in mixing clear paste, add the succinum fine powder afterwards, add the starch of 100～400 unit of weights again, mixing, drying, powder becomes fine powder, adds Radix et Rhizoma Nardostachyos volatile oil, mixing incapsulates, promptly.
9, the ARR preparation method of Chinese medicine of a kind of treatment as claimed in claim 5 is characterized in that: Succinum powder is broken into fine powder; Radix Et Rhizoma Nardostachyos extracts volatile oil, and the aqueous solution after distillation device is in addition collected; Radix Notoginseng powder is broken into coarse powder, adds 50%～80% alcohol reflux 2～3 times, and each 1～3 hour, filter, relative density is 1.25～1.30 clear paste when merging solution and its concentrating under reduced pressure being become 60 ℃; Get Radix Notoginseng, the Radix Et Rhizoma Nardostachyos medicinal residues decoct with water secondary with Radix Codonopsis, Rhizoma Polygonati, 1～2 hour for the first time, 0.5～1.5 hour for the second time, make the aqueous solution merging after twice decocting liquid and the distillation of aforementioned Radix Et Rhizoma Nardostachyos, filter, relative density was 1.20～1.25 clear paste when filtrate was condensed into 60 ℃; With this clear paste and Radix Notoginseng clear paste merge, mixing, in mixing clear paste, add the succinum fine powder afterwards, add the dextrin of 100～550 unit of weights and the sucrose of 100～700 unit of weights again, mixing is made granule; With the particle drying that makes, the spray Radix et Rhizoma Nardostachyos volatile oil, mixing, promptly.
10, the ARR preparation method of Chinese medicine of a kind of treatment as claimed in claim 7, it is characterized in that: Succinum powder is broken into fine powder; Radix Et Rhizoma Nardostachyos extracts volatile oil, and the aqueous solution after distillation device is in addition collected; Radix Notoginseng powder is broken into coarse powder, adds 50%～80% alcohol reflux 2～3 times, and each 1～3 hour, filter, relative density is 1.25～1.30 clear paste when merging solution and its concentrating under reduced pressure being become 60 ℃; Get Radix Notoginseng, the Radix Et Rhizoma Nardostachyos medicinal residues decoct with water secondary with Radix Codonopsis, Rhizoma Polygonati, 1～2 hour for the first time, 0.5～1.5 hour for the second time, make the aqueous solution merging after twice decocting liquid and the distillation of aforementioned Radix Et Rhizoma Nardostachyos, filter, relative density was 1.20～1.25 clear paste when filtrate was condensed into 60 ℃; With this clear paste and Radix Notoginseng clear paste merge, mixing, in mixing clear paste, add the succinum fine powder afterwards, mixing, drying, powder becomes fine powder; Add the starch of Radix et Rhizoma Nardostachyos volatile oil and 100～400 unit of weights and the magnesium stearate of 0.8～5 unit of weight again, mixing, granulation, tabletting, coating, promptly.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 01131734 CN1215853C (en) | 2001-09-28 | 2001-09-28 | Traditional Chinese medicine for curing arrhythmia and its preparation |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 01131734 CN1215853C (en) | 2001-09-28 | 2001-09-28 | Traditional Chinese medicine for curing arrhythmia and its preparation |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1408389A CN1408389A (en) | 2003-04-09 |
| CN1215853C true CN1215853C (en) | 2005-08-24 |
Family
ID=4670816
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN 01131734 Expired - Lifetime CN1215853C (en) | 2001-09-28 | 2001-09-28 | Traditional Chinese medicine for curing arrhythmia and its preparation |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1215853C (en) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN100396279C (en) * | 2004-12-01 | 2008-06-25 | 山东步长制药有限公司 | Chinese medicinal preparation for treating arrhythmia and its preparation method |
| CN101088548B (en) * | 2006-06-14 | 2010-04-07 | 山东步长制药有限公司 | Chinese medicine prepn for treating arrhythmia and its prepn process and quality control method |
| CN101088549B (en) * | 2006-06-14 | 2010-05-12 | 山东步长制药有限公司 | Chinese medicine preparation for treating arrhythmia and its preparation process and quality control method |
| CN101433669B (en) * | 2008-12-03 | 2011-03-23 | 山东步长制药有限公司 | Use of pharmaceutical composition in preparing medicament for preventing and treating allergic diseases |
| CN102614369B (en) * | 2011-01-26 | 2014-11-26 | 北京因科瑞斯医药科技有限公司 | Medicinal composition for treating arrhythmia, and preparation method thereof |
| CN102836320B (en) * | 2012-10-08 | 2013-09-04 | 河南中医学院 | Chinese medicinal pill for treating tachyarrhythmia |
-
2001
- 2001-09-28 CN CN 01131734 patent/CN1215853C/en not_active Expired - Lifetime
Also Published As
| Publication number | Publication date |
|---|---|
| CN1408389A (en) | 2003-04-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN1240416C (en) | Medicine for curing hypertension and its preparation method | |
| CN1772196A (en) | Heart failure regulating Chinese medicine | |
| CN101670011A (en) | Medicament for treating rheumatism and rheumatoid and preparation method thereof | |
| CN1294944C (en) | Chinese medicinal preparation for treating breast impediment | |
| CN1215853C (en) | Traditional Chinese medicine for curing arrhythmia and its preparation | |
| CN100337660C (en) | Hypertension treating Chinese medicine composition | |
| CN1733242A (en) | Medicine for curing qi deficiency induced thoracic obstruction (coronary heart disease) and technique for preparing the same | |
| CN101032604A (en) | Chinese medicine preparation for curing vascular type headache | |
| CN1840170A (en) | Chinese proprietary medicine for treating cerebral thrombosis | |
| CN115177669A (en) | Traditional Chinese medicine composition with effect of treating myocardial bridge and application thereof | |
| CN1872308A (en) | Preparation of Chinese traditional medicine for treating pulmonary tuberculosis | |
| CN1772096A (en) | Arrhythmia treating Chinese medicine composition | |
| CN103585414B (en) | Pharmaceutical composition for treating sciatica and osteoporosis | |
| CN1107711A (en) | Hypoglycemic compound capsule | |
| CN1111054C (en) | Medicine for treating apoplexy and its preparing process | |
| CN1245197C (en) | Chinese medicine preparation for treating coronary heart disease and viral myocarditis | |
| CN1182862C (en) | Chinese medicine prepn for treating coronary heart disease and angina pectoris and its prepn | |
| CN1247237C (en) | Medicinal composition for treating coronary disease and its preparation and application | |
| CN1076622C (en) | Chinese medicine for curing nephritis | |
| CN1238013C (en) | Myocarditis treating Chinese medicine prepn | |
| CN116211974B (en) | Traditional Chinese medicine composition for improving microcirculation of human body | |
| CN1241632C (en) | Chinese patent medicine for treating cardiac function failure and its preparation method | |
| CN1168473C (en) | Chinese medicine prepn for treating arterioscleriosis | |
| CN1440801A (en) | Dizziness treating Chinese medicine | |
| CN1168483C (en) | Heart disease treating medicine |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| ASS | Succession or assignment of patent right |
Owner name: SHANDONG BUCHANG PHARMACEUTICAL CO., LTD. Free format text: FORMER OWNER: YANG XIMING Effective date: 20071207 |
|
| C41 | Transfer of patent application or patent right or utility model | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20071207 Address after: No. 369 Zhonghua West Road, Heze, Shandong Patentee after: Shandong Buchang Pharmaceutical Co., Ltd. Address before: Li Zhongqun, Shanxi patent center, 11 Dayan Pagoda Road, Shaanxi, Xi'an Province Patentee before: Yang Ximing |
|
| C56 | Change in the name or address of the patentee | ||
| CP01 | Change in the name or title of a patent holder |
Address after: 274000 No. 369 Zhonghua West Road, Heze, Shandong Patentee after: Shandong Buchang Pharmaceuticals Co., Ltd. Address before: 274000 No. 369 Zhonghua West Road, Heze, Shandong Patentee before: Shandong Buchang Pharmaceutical Co., Ltd. |
|
| CX01 | Expiry of patent term |
Granted publication date: 20050824 |
|
| CX01 | Expiry of patent term |